Trial Profile
Long-Term Tolerability and Safety of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary) ; Hyaluronidase
- Indications Chronic inflammatory demyelinating polyradiculoneuropathy
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Acronyms ADVANCE-CIDP 3
- Sponsors Baxalta; Shire; Takeda
- 08 Mar 2024 The trial has been Discontinued in Italy, According to European Clinical Trials Database record.
- 16 Jan 2024 According to a Takeda media release, based on results from ADVANCE-CIDP 1 and ADVANCE-CIDP 3 trials U.S. Food and Drug Administration (FDA) has approved HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent the relapse of neuromuscular disability and impairment in adults.
- 07 Sep 2023 The trial has been completed in Croatia according to European Clinical Trials Database record.